Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Aptevo Therapeutics entered into warrant inducement agreements resulting in the cash exercise of existing warrants for 2,777,778 shares at a reduced price of $1.08 per share. The company received $3.0 million in gross proceeds and issued new 'reload' warrants for up to 13,888,890 additional shares to the participating holders. Proceeds will be used for working capital and general corporate purposes.
Beeline Holdings received a deficiency notice from Nasdaq on November 6, 2026, for failing to maintain a minimum bid price of $1.00 per share for 30 consecutive business days. The company has until May 5, 2027, to regain compliance, which requires the stock to close at $1.00 or higher for at least 10 consecutive business days.
OptimumBank Holdings closed a private placement offering of 1,290,322 shares of common stock to an institutional accredited investor at $7.75 per share. The transaction resulted in gross proceeds of approximately $10 million and was conducted as an unregistered sale of equity securities.
Globa Terra Acquisition M&A Deal with Nature’s Ledger Inc.
Globa Terra Acquisition Corp, a SPAC, has entered into a definitive business combination agreement with Nature’s Ledger Inc., a company focused on carbon credit development and environmental attribute marketing. Upon closing, the combined entity is expected to operate as a publicly traded corporation under the laws of Alberta, Canada. The transaction involves a series of mergers and continuances, including a PIPE financing to be completed by Nature's Ledger.
Vista Gold Corp. provided an update on its pending acquisition by Artemis Gold Inc. via a court-approved plan of arrangement. Under the agreement, Vista shareholders will receive 0.0966 of an Artemis common share for each Vista share, resulting in Vista becoming a wholly owned subsidiary of Artemis.
Counterparty
Artemis Gold Inc.
“We are confident that the transaction with Artemis represents a compelling opportunity to deliver value to our shareholders now and over the long term. In addition to providing an immediate premium to the market price of Vista shares, the Arrangement offers shareholders the opportunity to benefit from the ongoing expansion of the Blackwater operation and the potential development of Mt Todd as part of a larger, well-capitalized gold producer.”
FreeCast, Inc. notified Nasdaq that it is no longer in compliance with Audit Committee composition requirements following the immediate resignation of director William P. Jennings, Jr. on November 6, 2026. The company intends to restore compliance by appointing a replacement candidate as director and Audit Committee Chairperson effective November 17, 2026.
BHAV Acquisition Corp II announced the partial exercise of the underwriters' over-allotment option, resulting in the sale of 509,855 additional units for gross proceeds of approximately $5.1 million. Simultaneously, the company's sponsor, BHAV Partners II LLC, purchased an additional 5,098 private units for $50,980 to maintain trust account requirements.
Hometown Financial Group entered into an agency agreement with Keefe, Bruyette & Woods (KBW) to act as the exclusive marketing agent for its common stock offering. The offering is part of a mutual-to-stock conversion, with the company offering between 51 million and 69 million shares (potentially up to 79.35 million) at a fixed price of $10.00 per share.
DT Cloud Star Acquisition M&A Deal with PrimeGen US, Inc.
DT Cloud Star Acquisition Corp entered into the first amendment to its business combination agreement with PrimeGen US, Inc. The amendment extends the outside closing date to January 31, 2027, and clarifies the conversion of rights into ordinary shares during the redomestication merger.
InspireMD received FDA approval for its CGuard Prime TransCarotid Stent System for use in transcarotid artery revascularization (TCAR) procedures. This approval doubles the company's total addressable market in the U.S., providing access to over 35,000 annual procedures with its proprietary MicroNet technology.
Astec Industries Divestiture to Komatsu America Corp. for $75M
Astec Industries has entered into a definitive agreement to sell its road construction equipment business, including the Roadtec and Carlson brands, to Komatsu America Corp. for $75 million in cash. The divestiture of the loss-making business is expected to improve Astec's adjusted EBITDA margin by approximately 200 basis points and sharpen focus on its core higher-margin product portfolio.
Value
$75M
Counterparty
Komatsu America Corp.
“The Roadtec Business has been an important part of Astec, and I want to thank our Roadtec employees for their dedication and contributions and our customers for their partnership and loyalty over the years. We are pleased to have entered into this agreement with Komatsu, a strategic buyer who values the Roadtec brand, technology, engineering expertise and team members. This transaction is consistent with our strategy to sharpen our portfolio focus, drive sustainable margin expansion and allocate capital toward our core businesses and long-term growth opportunities.”
Jaco van der Merwe, Astec President and Chief Executive Officer
Live Oak Bancshares, Inc. closed an underwritten public offering of 4,000,000 depositary shares, each representing a 1/40th interest in its 8.750% Fixed Rate Series B Non-Cumulative Perpetual Preferred Stock. The offering raised approximately $96.25 million in net proceeds after underwriting discounts and expenses, with the shares carrying a liquidation preference of $25 per depositary share.
Mountain Crest Acquisition Corp. V M&A Deal with CubeBio Co., Ltd.
Shareholders of Mountain Crest Acquisition Corp. V approved the definitive business combination agreement with South Korea-based CubeBio Co., Ltd. The transaction will result in both companies becoming subsidiaries of a new entity, VIANIQ Holdings Limited (formerly CubeBio Holdings Limited). The approval marks a major step toward completing the merger and taking the combined entity public.
Rallybio Corp announced that its pending merger with Avenzo Therapeutics is expected to close following the close of trading on November 20, 2026. The company also provided a timeline update for its previously announced special cash distribution of $13.90 per share, which will be paid to stockholders of record as of November 5, 2026, following Nasdaq due bill procedures.
SmartStop Self Storage REIT Capital Raise of $334M
SmartStop Self Storage REIT entered into forward sale agreements for an aggregate of 9,372,500 shares of common stock at an initial forward price of $35.6125 per share. The offering includes 8,150,000 initial shares and 1,222,500 shares from the full exercise of the underwriters' overallotment option. The company intends to use the net proceeds from the eventual settlement of these agreements to fund pending investments, including a Canadian joint venture and potential acquisitions.
Advanced Drainage Systems M&A Deal with StormTrap Investments LLC
Advanced Drainage Systems, Inc. (ADS) has completed its acquisition of StormTrap Investments LLC from PSP Capital. The deal expands ADS's addressable market in highly engineered stormwater storage solutions and provides cross-selling opportunities within the water management industry.
Tempest Therapeutics Licensing Deal with Hebei Senlang Biotechnology Co., Ltd.
Tempest Therapeutics has exercised its option to obtain an exclusive license for Senlang’s CD7-targeted lentiviral in vivo CAR-T platform and associated candidates worldwide, excluding China. The deal includes the lead BCMA/GPRC5D dual-targeting candidate (TPST-4903) currently in a Phase 1 study for relapsed or refractory multiple myeloma. This exercise follows encouraging preliminary clinical data from 13 patients and expands Tempest's delivery capabilities alongside its existing LNP platform.
Counterparty
Hebei Senlang Biotechnology Co., Ltd.
“Our decision to exercise this option and obtain an exclusive license reflects our confidence in the platform and the differentiating clinical observations from the lead program.”
Matt Angel, Ph.D., President and Chief Executive Officer of Tempest
“With the addition of this clinical-stage lentiviral platform alongside our targeted LNP platform, we have expanded our capabilities to develop in vivo immune reset therapies for cancer and autoimmune disease.”
Matt Angel, Ph.D., President and Chief Executive Officer of Tempest
PepGen Inc. entered into an underwriting agreement to sell 25,000,000 shares of common stock at a public offering price of $5.00 per share. The company expects to raise approximately $125.0 million in gross proceeds (excluding the underwriters' 30-day option for an additional 3.75 million shares) to fund clinical development and general corporate purposes.
LifeStance Health Group M&A Deal with Selling Stockholders
LifeStance Health Group, Inc. entered into an underwriting agreement for a secondary offering of 45,000,000 shares of common stock sold by existing stockholders. The company did not receive any proceeds from the sale, but it repurchased 2,000,000 of these shares from the underwriters as part of the transaction.
Hagerty Signs $148M M&A Deal with Hagerty Holding Corp.
Hagerty, Inc. announced the pricing and closing of a secondary offering of 10,000,000 shares of Class A common stock by its majority stockholder, Hagerty Holding Corp., at $14.85 per share. The company did not receive any proceeds from the sale, as the shares were previously issued and the offering was intended to facilitate a secondary sale by the selling stockholder.
Candel Therapeutics entered into a Second Amended and Restated Open Market Sale Agreement with Jefferies LLC to establish a new at-the-market (ATM) equity facility. The agreement allows the company to sell up to $50 million of common stock from time to time, in addition to the $50 million previously sold under a prior 2025 agreement.
Beneficient received a deficiency notice from Nasdaq on November 5, 2026, because its market value of listed securities (MVLS) fell below the $35 million minimum requirement for 30 consecutive business days. The company has until May 4, 2027, to regain compliance by maintaining an MVLS of at least $35 million for at least ten consecutive business days. The notice has no immediate effect on the listing of the company's Class A common stock (BENF) or warrants (BENFW).
Rain Enhancement Technologies Holdco received a deficiency notice from Nasdaq on November 6, 2026, because its Class A common stock failed to maintain a minimum bid price of $1.00 for 30 consecutive business days. The company has until May 5, 2027, to regain compliance by maintaining a closing bid price of at least $1.00 for at least ten consecutive business days.
Rani Therapeutics received an additional 180-day extension from Nasdaq to regain compliance with the $1.00 minimum bid price requirement. As part of this process, the company's listing was transferred from the Nasdaq Global Market to the Nasdaq Capital Market effective November 12, 2026. The company now has until May 10, 2027, to meet the requirement, which may involve a reverse stock split if necessary.
Sempra Divestiture to Kohlberg Kravis Roberts & Co. L.P. for $9.9B
Sempra completed the sale of a 45% equity interest in Sempra Infrastructure Partners, LP to KKR and CPPIB for total consideration including $4.56 billion in cash and $5.34 billion in promissory notes. Following the transaction, Sempra retains a 25% interest and will deconsolidate the unit, expecting to record a gain on sale of up to $3.30 billion.
Value
$9.9B
Counterparty
Kohlberg Kravis Roberts & Co. L.P. and Canada Pension Plan Investment Board
Ardent Health Signs $47M M&A Deal with Boone Health
Ardent Health (NYSE: ARDT) has entered into a definitive agreement to acquire Boone Health, a Missouri-based not-for-profit health system, for $47 million in cash. The deal includes a 392-bed hospital and 19 sites of care, with Ardent committing an additional $200 million in capital investments over the next 10 years. The transaction is expected to close in Q1 2027 and be 6-8% accretive to Ardent's Adjusted EBITDA by the third year.
First Advantage M&A Deal with Silver Lake Group, L.L.C.
First Advantage Corporation announced the closing of a secondary offering of 15,000,000 shares of common stock by investment funds affiliated with Silver Lake Group. The company did not sell any shares and received no proceeds from the transaction, which served to facilitate the resale of shares by the selling stockholder. The offering closed on November 12, 2026, following the entry into an underwriting agreement with Barclays and J.P. Morgan.
Apollo Commercial Real Estate Finance Liquidating Trust Divestiture
Apollo Commercial Real Estate Finance, Inc. (ARI) completed its plan of liquidation by transferring all remaining assets and liabilities to the Apollo Commercial Real Estate Finance Liquidating Trust. ARI stockholders received non-transferable units of beneficial interest in the trust on a one-for-one basis, and ARI's common stock has been cancelled and deregistered from the SEC.
Rank One Computing M&A Deal with Zuccaro Technical Consulting LLC
Rank One Computing Corporation (ROC) filed this amendment to provide required audited and pro forma financial statements following its completed acquisition of Zuccaro Technical Consulting LLC (ZTC). The transaction, which closed on August 31, 2026, involved ROC acquiring all issued and outstanding membership interests of ZTC from ZTC Holdco, Inc.
Fulcrum Therapeutics Signs $7M M&A Deal with Slate Medicines, Inc.
Fulcrum Therapeutics entered into an agreement to sell its early-stage fetal hemoglobin (HbF) assets to an unaffiliated third-party pharmaceutical company for $7.0 million in cash. The sale is a strategic update to its pending merger with Slate Medicines, as the proceeds will be credited to Fulcrum's net cash and are expected to increase the cash dividend declared in connection with the merger.